zduran G, Becer E, Vatansever HS
The two RENEW-ALC trials (combined enrollment: 2,200 patients) began recruiting in late 2025, with primary completion expected in 2028 the largest Phase 3 trials of any GLP-1 agent for addiction
We break down the platform's licensing, pharmacy practices, customer feedback, and how it stacks up for GLP-1 and weight-loss prescriptions in 2026
Colorectal Cancer Risk This comes at a time when colorectal cancer is the third most commonly diagnosed cancer in both men and women and the second leading cause of cancer-related death in the United States
Key Takeaways GLP-1 receptor agonists have been linked to both positive and negative mental health outcomes
Drugs targeting weight management accounted for nearly half of the increase in drug spend in 2024, and the average list price for a GLP-1 is around $1,000 per month